Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Glibenclamide in patients with poorly controlled type 2 diabetes: A 12-week, prospective, single-center, open-label, dose-escalation study
Clinical Pharmacology: Advances and Applications, Volume 6, No. 1, Year 2014
Notification
URL copied to clipboard!
Description
Background: The purpose of this study was to investigate the effect of glibenclamide dose escalation on blood glucose and insulin in patients with poorly controlled type 2 diabetes. Methods: Twenty-two subjects with type 2 diabetes were administered increasing doses (0, 2.5, 5, 10, and 20 mg/day) of glibenclamide at 2-week intervals. Glibenclamide, glucose, and insulin determinations were performed. Results: The decrease in mean blood glucose from zero dose was 20%, 22%, 26%, and 28% for doses of 2.5, 5, 10, and 20 mg/day, respectively, which was significant from zero dose to 2.5 mg/day (P≤0.001). There were no significant decreases in glucose concentration beyond 2.5 mg/day. The percentage increase in mean insulin from zero dose was 51%, 58%, 44%, and 33% for 2.5, 5, 10, and 20 mg/day respectively. Mean blood insulin increased significantly from zero dose to 2.5 mg/day (P≤0.001). There were no significant increases in mean insulin concentration beyond 2.5 mg/day. Conclusion: The results of this study suggest that increasing doses of glibenclamide do not produce a proportional increase in insulin secretion or a proportional decrease in blood glucose concentration. © 2014 Rambiritch et al.
Authors & Co-Authors
Rambiritch, Virendra
South Africa, Durban
University of Kwazulu-natal
Maharaj, Breminand T.J.
South Africa, Durban
University of Kwazulu-natal
Naidoo, Poobalan
South Africa, Johannesburg
Boehringer Ingelheim
Statistics
Citations: 19
Authors: 3
Affiliations: 2
Identifiers
Doi:
10.2147/CPAA.S54809
e-ISSN:
11791438
Research Areas
Noncommunicable Diseases
Study Design
Cohort Study